Robert J. DeVita

Prof. Robert J. DeVita


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
CACourtney Ackeifi
Courtney Ackeifi
PWPeng Wang
Peng Wang
EKEsra Karakose
Esra Karakose
JFJocelyn E. Manning Fox
Jocelyn E. Manning Fox
BGBryan J. González
Bryan J. González
ASAndrew F. Stewart
Andrew F. Stewart
GLP-1 receptor agonists, widely used to treat diabetes, are converted to human β cell regenerative drugs by adding a DYRK1A inhibitor.

30 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KKKunal Kumar
Kunal Kumar
PWPeng Wang
Peng Wang
RSRoberto Sanchez
Roberto Sanchez
ESEthan A Swartz
Ethan A Swartz
ASAndrew F. Stewart
Andrew F. Stewart
RDRobert J. DeVita
Robert J. DeVita

8 March 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KKKunal Kumar
Kunal Kumar
CSChalada Suebsuwong
Chalada Suebsuwong
PWPeng Wang
Peng Wang
AGAdolfo Garcia-Ocana
Adolfo Garcia-Ocana
ASAndrew F. Stewart
Andrew F. Stewart
RDRobert J. DeVita
Robert J. DeVita

19 February 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KKKunal Kumar
Kunal Kumar
PWPeng Wang
Peng Wang
JWJessica Wilson
Jessica Wilson
VZViktor Zlatanic
Viktor Zlatanic
CBCecilia Berrouet
Cecilia Berrouet
RDRobert J. DeVita
Robert J. DeVita

16 January 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
CACourtney Ackeifi
Courtney Ackeifi
ESEthan Swartz
Ethan Swartz
KKKunal Kumar
Kunal Kumar
HLHongtao Liu
Hongtao Liu
SCSuebsuwong Chalada
Suebsuwong Chalada
PWPeng Wang
Peng Wang
Small molecule inhibitors of dual specificity, tyrosine phosphorylation-regulated kinase 1A (DYRK1A), including harmine and others, are able to drive human β cell regeneration. While DYRK1A is certainly a target of this class, whether it is the only or the most important target is uncertain. Here, we employ a combined pharmacologic and genetic approach to refine the potential mitogenic targets of the DYRK1A inhibitor family in human islets. A combination of human β cell RNA sequencing, DYRK1A inhibitor kinome screens, pharmacologic inhibitors, and targeted silencing of candidate genes confirms that DYRK1A is a central target. Surprisingly, however, DYRK1B also proves to be an important target: silencing DYRK1A results in an increase in DYRK1B. Simultaneous silencing of both DYRK1A and DYRK1B yields greater β cell proliferation than silencing either individually. Importantly, other potential kinases, such as the CLK and the GSK3 families, are excluded as important harmine targets. Finally, we describe adenoviruses that are able to silence up to 7 targets simultaneously. Collectively, we report that inhibition of both DYRK1A and DYRK1B is required for induction of maximal rates of human β cell proliferation, and we provide clarity for future efforts in structure-based drug design for human β cell regenerative drugs.

1 September 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KKKunal Kumar
Kunal Kumar
PUPeter Man-Un Ung
Peter Man-Un Ung
PWPeng Wang
Peng Wang
HWHui Wang
Hui Wang
HLHailing Li
Hailing Li
RDRobert J. DeVita
Robert J. DeVita